Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
EDITORIAL
Topical cyclosporine A in the management of dry eye disease in Sjögren’s syndrome
1
Department of Ophthalmology, Slovak Medical University and University Hospital in Bratislava, Slovakia
Publication date: 2024-12-19
Corresponding author
Nora Majtánová
Department of Ophthalmology, Slovak Medical University and University Hospital in Bratislava, 11 Antolska St., 851 07, Bratislava, Slovakia
Department of Ophthalmology, Slovak Medical University and University Hospital in Bratislava, 11 Antolska St., 851 07, Bratislava, Slovakia
Reumatologia 2024;62(6):395-397
REFERENCES (17)
1.
Dana R, Bradley JL, Guerin A, et al. Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System. Am J Ophthalmol 2019; 202: 47–54, DOI: 10.1016/j.ajo.2019.01.026.
2.
Cai Y, Wei J, Zhou J, Zou W. Prevalence and INCIDENCE of Dry Eye Disease in Asia: A Systematic Review and Meta-Analysis. Ophthalmic Res 2022; 65: 647–658, DOI: 10.1159/000525696.
3.
Cubuk MO, Ucgul AY, Ozgur A, et al. Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren’s syndrome versus non-Sjogren’s syndrome. Int Ophthalmol 2021; 41: 1479–1485, DOI: 10.1007/s10792-021-01708-1.
4.
Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis 2020; 79: 3–18, DOI: 10.1136/annrheumdis-2019-216114.
5.
Akpek EK, Bunya VY, Saldanha IJ. Sjögren’s Syndrome: More Than Just Dry Eye. Cornea 2019; 38: 658–661, DOI: 10.1097/ICO.0000000000001865.
6.
Barrientos RT, Godín F, Rocha-De-Lossada C, et al. Ophthalmological Approach for the Diagnosis of Dry Eye Disease in Patients with Sjögren’s Syndrome. Life (Basel) 2022; 12: 1899, DOI: 10.3390/life12111899.
7.
Periman LM, Mah FS, Karpecki PM. A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments. Clin Ophthalmol 2020; 14: 4187–4200, DOI: 10.2147/OPTH.S279051.
8.
Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol 2009; 54: 321–338, DOI: 10.1016/j.survophthal.2009.02.002.
9.
Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003; 22: 640–650, DOI: 10.1097/00003226-200310000-00008.
10.
Grubbs JR Jr, Tolleson-Rinehart S, Huynh K, Davis RM. A review of quality of life measures in dry eye questionnaires. Cornea 2014; 33: 215–218, DOI: 10.1097/ICO.0000000000000038.
11.
Retamozo S, Baldini C, Bootsma H, et al. Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren’s Syndrome. Drugs Aging 2021; 38: 265–284, DOI: 10.1007/s40266-021-00838-6.
12.
Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000; 107: 967–974, DOI: 10.1016/s0161-6420(00)00035-x.
13.
Gao M, Zhao L, Liang R, et al. Evaluation of the Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops (II) in the Treatment of Dry Eye Associated with Primary Sjögren’s Syndrome. Ocul Immunol Inflamm 2023; 31: 1662–1668, DOI: 10.1080/09273948.2022.2094812.
14.
Baudouin C, Figueiredo FC, Messmer EM, et al. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol 2017; 27: 520–530, DOI: 10.5301/EJO.5000952.
15.
Fujita M, Igarashi T, Kurai T, et al. Correlation between dry eye and rheumatoid arthritis activity. Am J Ophthalmol 2005; 140: 808–813, DOI: 10.1016/j.ajo.2005.05.025.
16.
Chan YH, Sun CC. Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen. Taiwan J Ophthalmol 2023; 13: 68–74, DOI: 10.4103/tjo.TJO-D-22-00140.
17.
Straub M, Bron AM, Muselier-Mathieu A, Creuzot-Garcher C. Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up. Br J Ophthalmol 2016; 100: 1547–1550, DOI: 10.1136/bjophthalmol-2015-306930.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
